Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the understanding of how the immune system changes when patients receive treatment for lymphomas by looking at the antibody levels and the level of the different cells that make up the immune system over time compared to those without lymphoma.
Full description
PRIMARY OBJECTIVE:
I. To determine the seroprotection and seroconversion rates after influenza or SARS-CoV2 vaccination in patients with lymphoma receiving active treatment or in follow up observation.
SECONDARY OBJECTIVES:
I. To characterize virus-specific plasmablasts and memory B cells after vaccination in patients with lymphoma receiving active treatment or in follow up observation.
II. To investigate the longevity of viral-specific humoral immunity to influenza virus in patients with lymphoma receiving active treatment or in follow up observation.
III. To assess the timing and strength of the peak immune response to vaccination.
IV. To assess the effect of different lymphomas and treatment modalities in the immune response to vaccination.
OUTLINE:
Patients receive seasonal inactivated influenza vaccine intramuscularly (IM) at day 0.
After completion of study treatment, patients are followed up at days 7, 28, 90, 180, and 365.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects with a diagnosis of lymphoma falling into the following categories:
Subject capable of providing written or electronic informed consent prior to initiation of any study procedures; subjects able to understand and comply with planned study procedures and be available for all study visits.
Hematology:
Hemoglobin: 7.0-16.1 gm/dL
Platelet count: 10-600/µL
Subjects who have not received the seasonal influenza vaccine in the current flu season and are not suspected to have had an influenza infection in the current flu season *- Platelet count: 10-600/uL
Exclusion criteria
200 participants in 3 patient groups
Loading...
Central trial contact
Andres Chang, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal